Linda Petrone

TL;DR: Immune response to SARS-CoV-2 peptides in a whole-blood assay is associated to COVID-19 and it is characterized by both Th1 and Th2 profile, which may be useful for developing new T-cell based diagnostic tests for disease and vaccine settings.

TL;DR: Data from controlled trials, national registries of biologics, and postmarketing surveillance show that the risk of TB reactivation in patients receiving non-anti-TNF-targeted biologicics is negligible, raising the question whether the screening procedures for LTBI would be necessary.

TL;DR: The epidemiology and immunology of these viral infections and their interactions with TB are discussed with implications for diagnosis, treatment and prevention of airborne infections (infection control, viral containment and workplace safety).

TL;DR: Beyond the supportive therapy, up to now the best therapeutic approach for COVID-19 may be a three-step combination therapy, including remdesivir 100mg/day in the first stage of the disease, and combined dexamethasone 6 mg/day plus baricitinib 4 mg/ day to target the immune dysregulation triggered by the SARS-CoV-2 infection.

TL;DR: QFT-Plus is more sensitive compared to QFT-GIT for active-TB detection, mainly due to TB2 responses, as shown in the meta-analysis.